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DAY 1, SUNDAY, NOVEMBER 18, 2018 
13.00 – 18.30 REGISTRATION for ISRT 2018 
14.00 – 16.00 SCIENTIFIC SESSION 1: NUCLEAR CARDIOLOGY 
 Moderators: Juhani Knuuti, Turku, Finland and Pietro Muto, 
Naples, Italy 
14.00 – 14.30 O1    Revolution in cardiac imaging: Quantitative perfusion, 
inflammation and hybrid imaging   Juhani Knuuti, Turku, Finland 
 
14.30 – 15.00 O4 Novel therapies of cardiac regeneration. How imaging can help 
in diagnosis, targeting and monitoring?  Seppo Ylä-Herttuala, 
Kuopio, Finland  
 
15.00 – 15.30 O2  Imaging innervation.  Finally clinical applications?  
Albert Flotats, Barcelona, Spain 
15.30 – 16.00 O3 Gauging cardiac repair, regeneration and inflammation with 
new molecular probes James Thackeray, Hannover, Germany  
 
16.00 – 16.30 COFFEE & TEA BREAK 
16.30 – 18.45 SCIENTIFIC SESSION 2: NEW TRENDS IN ONCOLOGY AND 
PRECISION MEDICINE.  
 Moderators: Vivek Subbiah, MDACC, Houston, TX, USA and 
Homer Macapinlac, MDACC, Houston, TX, USA 
16.30 – 16.55 O5  Personalized medicine and precision oncology, Vivek Subbiah, 
Investigational Cancer Therapeutics, UT MD Anderson Cancer Center 
16.55 – 17.20 O6  Precision oncology in rare tumors: adopting the orphans, 
Roman Groisberg, Division of Medical Oncology, Rutgers Cancer 
Institute of New Jersey, New Brunswick, NJ, USA 
17.20 – 17.45 O7  Optimizing patient selection for phase 1 clinical trials: lessons 
from targeted therapy and immunotherapy drug development, 
Shiraj Sen, Drug Development, Sarah Cannon Research Institute at 
HealthOne; Denver, CO, USA 
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17.45 – 18.20 O8 Target discovery for precision oncology using large public 
databases, Jason Roszik, Department of Genomic Medicine, UT MD 
Anderson Cancer Center  
18.20 – 18.45 O12  Re-188 Lipiodol Liver Cancer Project – an update on current 
status, Ajit Shinto, Coimbatore, India 
WARMTH CONGRESS DINNER 1  
19.30 – 22.30 Restaurant Meripaviljonki 
 
 
DAY 2, MONDAY, NOVEMBER 19, 2018 
08.00 – 18.00 REGISTRATION for ISRT 2018 
09.00 – 11.00 OPENING CEREMONY  
Welcome Address Partha Choudhury, President-Elect, WARMTH  
Opening Remarks Kalevi Kairemo, Congress President, ISRT-2018, WARMTH  
Welcome Address Pirkko Mattila,  Minister of Health, Finland 
WARMTH Candle Lighting Ceremony    WARMTH Board Members 
AJIT PADHY ORATION Steven M. Larson, MSKCC, NY, USA  
O10  “New Insights in Theragnostics” 
presenter  Andrew M. Scott, Melbourne, Australia 
11.00 – 11.30  COFFEE & TEA BREAK 
 
 
11.30 – 13.00 SCIENTIFIC SESSION 3:  RADIOEMBOLISATION  AND LIVER 
THERAPIES   
Moderators: Patrick Flamen, Brussels, Belgium and Aviral Singh, 
Bad Berka, Germany 
11.30 – 11.55 O11  Personalized SIRT based on predictive dosimetry, regional 
functional reserve measurement and molecular imaging, Patrick 
Flamen, Jules Bordet Institute, Brussels, Belgium  
11.55 – 12.20 O9  Oncolytic viruses, Akseli Hemminki, University of Helsinki  
12.20 – 12.40 O13  Biologic dosimetry in SIRT, Katherine Vallis, University of Oxford, UK 
12.40 – 13.00 O14 Intra-arterial PRRT of SSTR-expressing liver tumors, Aviral 
Singh, Bad Berka, Germany 
Posters:       P1  The quantitative analysis of post-selective internal radiation 
therapy (SIRT) 90Y microspheres PET/CT in hepatocellular 
carcinoma in comparison with 99mTc-labelled macroaggregated 
albumin (MAA) planar and SPECT/CT, Ngoc Ha Le, Tran Hung Dao 
Hospital, Ho Chi Minh City, Vietnam 
 
13.00 – 14.00  LUNCH AT THE CONGRESS CENTER PAASITORNI 
14.00 – 16.00 SCIENTIFIC SESSION 4: NEW RADIONUCLIDE THERAPIES / 
RADIATION HAZARDS/ SAFETY ISSUES 
 Moderators: Seigo Kinuya, Kanazawa, Japan and Kazuko Ohno, 
Fukushima, Japan 
14.00 – 14.30 O15 Boron neutron capture therapy and world’s first accelerator-
based BNCT facility at Southern Tohoku General Hospital, 
Yoshihiro Takai,  Southern Tohoku BNCT Research Center, Japan 
14.30 – 15.00 O16 What did we learn from the Fukushima accident? Ohtsura Niwa, 
Radiation Effects Research Foundation, Hiroshima/ Nagasaki, Japan 
15.00 – 15.30 O17 Regulatory nuclear safety aspects, Linear No-Threshold 
Hypothesis of risk from low-level radiation exposure, Bennett S 
Greenspan, Society of Nuclear Medicine and Molecular Imaging, USA 
PANEL-discussion: Regulatory/ nuclear safety aspects 
Moderators: Seigo Kinuya, Kazuko Ohno and Bennet S Greenspan 
 
Posters:       P2 Establishment of incident reporting programme and lesson 
learnt in unsealed radionuclide therapy, Noreen Marwat, Nuclear 
Medicine Oncology and Radiotherapy Institute, Pakistan 
P3 Practices across Pakistan how medical emergency is handled in 
case of patients who has undergone unsealed  radionuclide 
therapy, Noreen Marwat, Nuclear Medicine Oncology and Radiotherapy 
Institute, Pakistan 
 
16.00 – 16.30 COFFEE & TEA BREAK 
16.30 – 18.15 SCIENTIFIC SESSION 5: PROSTATE CANCER: PSMA RADIOLIGAND 
  THERAPY (PRLT) – WHAT DO WE KNOW AND WHAT IS NEW?  
  Moderator: Richard P. Baum, Bad Berka, Germany 
16.30 – 16.45 O18 Introduction to PRLT, Richard P. Baum 
16.45 – 17.00 O19 Dosimetry following Lu-177 PSMA radioligand therapy and an 
insight into novel nadionuclides for theranostics of prostate 
cancer, Aviral Singh, Bad Berka, Germany 
17.00 – 17.15 O20 Dosimetry in PSMA radioligand therapy of metastasized 
prostate cancer using Lu-177 PSMA I&T and Lu-177 PSMA-617 
Christiane Schuchardt, Bad Berka, Germany 
17.15 – 17.45 O21  PSMA targeting and therapy trials in Australia, Andrew M. Scott, 
Melbourne, Australia 
17.45 – 18.00 O22 Ac-225- and Bi-213- PSMA-617 radioligand therapy in patients 
with castration resistant prostate cancer, Mike Sathekge, Pretoria, 
South Africa 
18.00 – 18.15 O23  [18F]AIF-PSMA-HBED-CC and 177Lu-PSMA-617 as a potential 
theragnostic tandem and comparison with 68Ga-PSMA-HBED-
CC in high-risk prostate cancer patients at initial staging, Omar 
Alonso, CUDIM, Montevideo, Uruguay 
Posters:      P4 177Lutetium-prostate-specific membrane antigen radionuclide    
treatment of lymph node metastatic prostate cancer with PSA 
recurrence: A cohort study, Finn Edler von Eyben, Odense, Denmark 
                     P5 Dosimetry in Molecular Radiotherapy - Bad Berka Experience, 
Christiane Schuchardt, Bad Berka, Germany 
P6 Web-Monitoring Tool for 177Lutetium-PSMA Treatments in 
Prostate Cancer Patients, Kalevi Kairemo, Helsinki, Finland  
 
18.25  Tram transportation to the City Hall in front of the Scandic Paasi hotel 
(Hakaniemi Square stop 0252) 
WARMTH CONGRESS DINNER 2  
19.00 – 20.30 CITY HALL of Helsinki, Mayor Reception 
20.45 -21.45 Tram transportation from the City Hall (Market Square stop) to the 
Scandic Paasi hotel (Hakaniemi Square) including sightseeing in Helsinki 
 
DAY 3, TUESDAY, NOVEMBER 20, 2018 
08.00 – 08.45  REGISTRATION for ISRT 2018 
8.45 – 11.00 SCIENTIFIC SESSION 6: THYROID CANCER – QUO VADIS? 
 Moderators: Mark Tulchinsky, PA; USA & Raihan Hussain, Dhaka, 
Bangladesh 
Debating Controversies in Radioiodine Imaging and Therapy of 
Thyroid Cancer 
8.45 – 9.00 O24  Introduction-thyroid cancer management, Mark Tulchinsky, 
Hershey, PA, USA 
9.00 – 9.15 O25  Total vs. subtotal thyroidectomy. East, West , what´s the best? 
Ilya V. Sleptsov, St. Petersburg, Russia 
9.15 – 9.30 O26  Dosimetric approach of thyroid cancer, Henry Bom, Chonnam, 
South Korea 
9.30 – 9.45 O27 Management of I-131 refractory thyroid cancer: a 
multimodality approach, Partha Choudhury, New Delhi, India 
9.45 – 9.55 O28 Prevalence of genetic duet and its influence on the prognosis of 
differentiated papillary thyroid carcinoma patients, Sanjana 
Ballal, New Delhi, India 
9.55 – 10.00 O29           Comments -thyroid cancer management, Raihan Hussain, Dhaka, 
Bangladesh 
Panel discussion:  Moderator Mark Tulchinsky 
Panelists:  Raihan Hussain, Henry Bom, Partha Choudhury and  
 Ilya Sleptsov, St. Petersburg, Russia 
10.05 – 10.30  "Radioiodine Imaging Before, After, Both or Neither ... and 
How?" 
10.30 – 10.55  "Controversies in Radioiodine Side-Effects: Confusion About 
Salivary Damage and Secondary Malignancy" 
Posters:      P7 Antithyroglobulin antibody as a marker of successful ablation 
therapy  in differentiated thyroid cancer, Ayu Rosemeilia Dewi, 
Universitas Padjadjaran, Indonesia 
P8 Importance  of isolated raised thyroglobulin antibody in follow 
up  and management of differentiated thyroid cancer, Ray 
Soumendranath, Tata Medical Center, Kolkata, India 
P9 Contribution of manual fusion in thyroid cancer whole body 
study with I-131. Case Report, Mariela Agolti, Parana, Argentina 
P10 Contribution of manual fusion in thyroid cancer whole body 
study with I-131, Mariela Agolti, Parana, Argentina 
 
11.00 – 11.10 Lifetime Achievement Awards & Group Photo  
Irene Virgolini, President, WARMTH & Kalevi Kairemo 
11.10 – 11.30 COFFEE & TEA BREAK 
 
11.30 – 13.00 SCIENTIFIC SESSION 7: PEPTIDE RECEPTOR/ NEW THERAPIES 
  Moderator: Irene Virgolini, Innsbruck, Austria 
 
11.30 – 11.45 O30           Value of FDG in NET: importance of dual tracer imaging,  
Margarida Rodrigues Radischat, Innsbruck, Austria 
11.45– 12.00 O31            Value of Re-PRRT in NET, Anna Yordanova, Bonn, Germany 
12.00– 12.15 O32            PRRT in G3-NEN, Aviral Singh, Bad Berka, Germany 
12.15– 12.35 O33          New peptides for PRRT in Non-NETs, Irene Virgolini, Innsbruck, 
Austria 
 
12.35– 12.50 O34          Long-term side effects and quality of life, patients view 
Josh Mailman, San Francisco, USA 
 
12.50– 12.58 O35          A correlation between c-Fos expression and radioiodine in 
breast cancer cell lines, Aisyah Elliyanti, Andalas University/ 
Dr.M.Djamil Hospital, Indonesia 
Posters:       P11 First ex-vivo experience with I- radiation and radioguided 
surgery technique in meningioma and neuroendocrine patients, 
Chiara Maria Grana, European Institute of Oncology, Milan, Italy 
P12 Lutetium-labelled DOTA-TOC and radionuclide therapy (PRRT) 
in China: First Experience, Feng Wang, Nanjing, China 
P13 Developing neuropeptide Y (NPY) nanoconstructs as potential 
theranostic agents, Irfan Ullah Khan, Institute of Nuclear Medicine & 
Oncology, Lahore, Pakistan 
 
13.00 – 14.00 LUNCH AT THE CONGRESS CENTER PAASITORNI 
 
14.00 – 16.00 SCIENTIFIC SESSION 8: NEW ALPHA- THERAPIES 
 Moderators: Oyvind Bruland, Oslo, Norway and Roy Larsen, Oslo, 
Norway 
14.00– 14.30 O36          Predicting the future of Alpha: clinical indications and 
radioisotopes of choice? Jean-Francois Chatal, Arronax, Nantes, 
France  
14.30– 14.50 O37        Radiometabolic therapy with 223Ra-dichloride: the European 
Institute of Oncology experience, Chiara Maria Grana, European 
Institute of Oncology,Milan, Italy 
14.50– 15.10 O38        Ra-223 in osteosarcoma –Ph I-trial, Vivek Subbiah, MD Anderson 
Cancer Center, USA 
15.10– 15.30 O39        Ra-224 labelled biodegradable carbonate microparticles 
(RadspherinR) to combate microscopical residual peritoneal 
carcinomatosis, Tina Bønsdorf, Oncoinvent AS, Oslo, Norway 
15.30– 15.50 O40       “Dual-alpha” - an expanding technology for development of 
targeted alpha therapies, Asta Juzeniene, Norwegian Radium 
Hospital, Oslo, Norway 
Posters:     P14  Clinical case of benefit due to deviation in Ra-223 treatment 
schedule, Tatiana Kochetova, MRRC, Obninsk, Russia  
P15   Personalized molecular imaging with bone scintigraphy, NaF-
PET, and FDG-PET for  evaluation of osteosarcoma response to 
Radium-223, Kalevi Kairemo, Houston, TX, USA  
P16   Treatment response evaluation in soft-tissue osteosarcoma 
metastases using fluoride-18 (18F)-PET/CT radiomics  analysis 
for 223Ra-therapy, Kalevi Kairemo, Houston, TX, USA 
P17  Substantiation of an individual therapeutic dose of 153Sm-
oxabiphor  for the treatment  of bone metastases, Ganna 
Grushka, Grigorev Institute for Medical Radiology, Ukraine 
P18   Radionuclide therapy for bone pain palliation in anemic 
patients: role of erythropoietin, Sukanta Barai, Sanjay Gandhi 
Postgraduate Institute of Medical Sciences, Lucknow, India 
P19  18F-fluoroethyltyrosine PET/CT: the European Institute of 
Oncology experience in brain tumors, Chiara Maria Grana, 
European Institute of Oncology, Milan, Italy 
P20  Pharmaceutical development of the therapeutic 
radiopharmaceutical  based on –emitting Sm-153 in heat-
sensitive carrier for brachytherapy of tumors of various 
locations, NM Tolbit, Karpov Institute, Obninsk, Russia 
 
15.50 – 16.20 COFFEE & TEA BREAK 
16.20 – 17.00 SCIENTIFIC SESSION 9: FUTURE ASPECTS OF COLLABORATION OF 
  WARMTH, IAEA AND WFNMB – ROUND TABLE DISCUSSION 
  Moderator: Irene Virgolini, Innsbruck, Austria 
  WARMTH perspective, Partha Choudhury, President-Elect 
  IAEA Perspective, NN, Vienna 
WFNMB perspective, Andrew M. Scott, Melbourne, Australia 
SNMMI perspective, Bennett Greenspan, USA 
O41 Presentation of ICRT 2019, Feng Wang, Nanjing, China  
 O42 Closing remarks, Kalevi Kairemo  
